AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AstraZeneca is conducting a real-world study titled ‘Multicentre, Single Arm, Non-interventional, Observational, Prospective Study to Assess Demographic Characteristics, Burden of Disease and Short-term Patient Reported Outcomes on Symptom Relief in Severe Asthma Patients Aged Older Than 12 Qualifying for Treatment With Tezepelumab in Russia.’ The study aims to evaluate the efficacy of Tezepelumab in patients with severe asthma, focusing on patient-reported outcomes and demographic characteristics.
The intervention being tested is Tezepelumab, an add-on maintenance treatment for severe asthma. It is designed to improve symptom relief and quality of life for patients suffering from this condition.
The study is observational, meaning it does not involve any intervention into routine clinical practice. It is a non-comparative, prospective cohort study that collects both retrospective and prospective data from participants.
The study began on September 10, 2024, with an anticipated completion timeline of approximately two years, or until data from 110 eligible patients is collected. The last update was submitted on August 11, 2025.
This update could influence AstraZeneca’s stock performance positively by demonstrating the company’s commitment to addressing severe asthma, potentially enhancing investor confidence. Competitors in the asthma treatment market may also be impacted as real-world evidence of Tezepelumab’s efficacy becomes available.
The study is ongoing, with further details accessible on the ClinicalTrials portal.